IP Library Granted Patent US 10,359,429
Granted Patent B2
US 10,359,429 · App. 14/995,894 · Granted Jul 23, 2019

Tagged ligands for enrichment of rare analytes from a mixed sample

Inventors: Allyn Forsyth (San Diego, CA); Helen Barnes (San Diego, CA)
Assignee: GPB Scientific, LLC
G01N33/57492B01L3/502761G01N1/405G01N33/54326G01N33/574G01N33/585B01L2200/0647B01L2300/0861B01L2400/086G01N2333/705Y10S435/971Y10S435/973Y10T436/101666Y10T436/13Y10T436/25125Y10T436/25375
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,359,429
App. No.
14/995,894
Granted
Jul 23, 2019
Kind
B2
Abstract

Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed.

Claims (30)

1. A method for enriching rare analytes from a sample, comprising:

a) contacting said sample with an affinity-tagged ligand (ATL) complex wherein said ATL complex comprises:

i) an affinity tag comprising a magnetic particle; and

ii) at least a first ligand and a second ligand different from said first ligand, wherein said first ligand and said second ligand are linked to said affinity tag; and wherein said first ligand and said second ligand selectively bind different markers of said rare analytes, thereby labeling said rare analytes with said ATL complex;

b) flowing said sample comprising said ATL complex-labeled rare analytes through a microfluidic enrichment device comprising an array of obstacles, wherein said obstacles are arranged in rows offset from other obstacles to create restricted and expanded gaps and to thereby laterally displace ATL complex-labeled rare analytes based on their hydrodynamic size, and wherein at least some of said obstacles are coated or treated with one or more capture moieties that capture the labeled rare analytes;

wherein said capture moieties comprise a magnet or magnetized substrate that interacts with the magnetic particle of the affinity tag, to selectively enrich said labeled rare analytes.

2. The method of claim 1 , wherein contacting said sample with an ATL complex is performed in solution.

3. The method of claim 1 , wherein said affinity tag is linked to at least one of said first ligand and said second ligand via one or more linkers.

4. The method of claim 3 , wherein said one or more linkers comprise at least one of: modified dextran; polyethylene glycol; polypropylene glycol; polyvinyl alcohol; polyvinylpyrrolidone; and polyethylene acrylamide.

5. The method of claim 1 , wherein said first ligand comprises a first antibody and said second ligand comprises a second antibody different from said first antibody.

6. The method of claim 5 , wherein said first antibody binds to a first marker for said rare analytes and said second antibody binds to a second marker of said rare analytes, and wherein said first marker is different from said second marker.

7. The method of claim 5 , wherein at least one of said first antibody and said second antibody is an Epithelial Cell Adhesion Molecule (EpCAM) antibody.

8. The method of claim 1 , wherein said one or more markers comprise one or more cancer markers.

9. The method of claim 1 , wherein said rare analytes comprise rare cells.

10. The method of claim 9 , wherein said rare cells comprise circulating tumor cells.

11. The method of claim 1 , wherein said sample comprises blood.

12. The method of claim 11 , wherein said rare analytes comprise rare cells.

13. The method of claim 1 , wherein said affinity tag reversibly binds to said capture moieties.

14. A method for enriching leukocytes or stem cells in a sample comprising:

a. contacting said sample with an affinity-tagged ligand (ATL) complex, wherein said ATL complex comprises:

i. an affinity tag comprising a magnetic particle; and

ii. at least a first ligand and a second ligand different from said first ligand, wherein said first ligand and said second ligand are linked to said affinity tag, and wherein said first ligand and said second ligand selectively bind different markers of said leukocytes or stem cells, thereby labeling said leukocytes or stem cells with said ATL complex;

b. flowing said sample comprising said ATL complex-labeled leukocytes or stem cells through a microfluidic device comprising an array of obstacles, wherein said obstacles are arranged in rows offset from other obstacles and that laterally displace the ATL complex-labeled leukocytes or stem cells based on their hydrodynamic size; and

c. flowing said sample comprising said ATL complex-labeled specific cells that have been flowed through the microfluidic device in step b) through an enrichment device comprising a surface functionalized with a capture moiety, wherein said capture moiety comprises a magnet or magnetized substrate that interacts with the magnetic particle of the affinity tag on the ATL complex-labeled leukocytes or stem cells to selectively enrich said ATL complex-labeled specific cells.

15. The method of claim 14 wherein at least one ligand is an antibody.

16. The method of claim 15 wherein said antibody is an anti-leukocyte associated receptor antibody.

17. The method of claim 15 wherein at least one of said antibodies is an anti-leukocyte associated receptor antibody.

18. The method of claim 14 , wherein both the first ligand and said second ligand are antibodies.

19. The method of claim 14 , wherein said affinity tag is linked to at least one of said first ligand and said second ligand via one or more linkers.

20. The method of claim 19 , wherein said one or more linkers comprise at least one of modified dextran, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, and polyethylene acrylamide.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Jun 14, 2024
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: GPB SCIENTIFIC, INC.
Reel/Frame 067732/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2024
From: CURATE (ABC), LLC
To: ZEON CORPORATION
Reel/Frame 067737/0769 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2024
From: GPB SCIENTIFIC, INC. (D/B/A CURATE BIOSCIENCES)
To: CURATE (ABC), LLC
Reel/Frame 067737/0738 →
SECURITY INTEREST Recorded Sep 28, 2023
From: GPB SCIENTIFIC, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY
Reel/Frame 065082/0354 →
CHANGE OF NAME Recorded Aug 30, 2020
From: GPB SCIENTIFIC, LLC
To: GPB SCIENTIFIC, INC.
Reel/Frame 053638/0375 →
CHANGE OF NAME Recorded Feb 10, 2016
From: CELLPOINT DIAGNOSTICS, INC.
To: CELLECTIVE DX CORPORATION
Reel/Frame 037759/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2016
From: CELLECTIVE DX CORPORATION
To: GPB SCIENTIFIC, LLC.
Reel/Frame 037694/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2016
From: FORSYTH, ALLYN; BARNES, HELEN
To: CELLPOINT DIAGNOSTICS, INC.
Reel/Frame 037694/0054 →
Continuity (5)
Continuation 14103352 · Dec 11, 2013
Continuation 13692710 · Dec 3, 2012
Continuation 13182003 · Jul 13, 2001
Division 12037077 · Feb 25, 2008
Related Publication 20170023578A1 · Jan 26, 2017
Cited By (2)
US 12,436,081 US 12,590,955